Literature DB >> 8100090

CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.

P A Monach1, H Schreiber, D A Rowley.   

Abstract

To test the importance of B lymphocytes in immunity to major histocompatibility complex class I alloantigens, B cell-deficient mice were generated by reconstituting severe combined immunodeficiency mice, which lack functional B and T lymphocytes, with T cells or with both T and B cells. The reconstituted mice were challenged with a cancer that expresses an MHC class I alloantigen at a low level and is susceptible to killing by CD8+ cytotoxic T lymphocytes. Tumors grew more slowly in and were rejected more frequently by the mice lacking B cells. Understanding the mechanism by which B cells suppress tumor allograft rejection may lead to new approaches for suppressing immune attack on transplanted tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100090

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.

Authors:  Shahrooz S Kelishadi; Agnes M Azimzadeh; Tianshu Zhang; Tiffany Stoddard; Emily Welty; Christopher Avon; Mitch Higuchi; Amal Laaris; Xiang-Fei Cheng; Christine McMahon; Richard N Pierson
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

2.  Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Authors:  Chih-Hang Tang; Shiun Chang; Ayumi Hashimoto; Yi-Ju Chen; Chang Won Kang; Anthony R Mato; Juan R Del Valle; Dmitry I Gabrilovich; Chih-Chi Hu
Journal:  Cancer Immunol Res       Date:  2018-04-12       Impact factor: 11.151

3.  Genetic changes occurring in established tumors rapidly stimulate new antibody responses.

Authors:  Michael T Spiotto; Michael A Reth; Hans Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

4.  Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype.

Authors:  M B Nelson; J K Nyhus; K I Oravecz-Wilson; E Barbera-Guillem
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

5.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

6.  Myeloid-derived suppressor cells promote B-cell production of IgA in a TNFR2-dependent manner.

Authors:  Xia Xu; Qinghong Meng; Ulrike Erben; Peigang Wang; Rainer Glauben; Anja A Kühl; Hao Wu; Chung Wah Ma; Minghua Hu; Yuanyuan Wang; Wei Sun; Junying Jia; Xinyi Wu; Wei Chen; Britta Siegmund; Zhihai Qin
Journal:  Cell Mol Immunol       Date:  2016-05-02       Impact factor: 11.530

Review 7.  Myeloid Cells as Targets for Therapy in Solid Tumors.

Authors:  Tiziana Cotechini; Terry R Medler; Lisa M Coussens
Journal:  Cancer J       Date:  2015 Jul-Aug       Impact factor: 3.360

8.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Generation and identification of tumor-evoked regulatory B cells.

Authors:  Arya Biragyn; Catalina Lee-Chang; Monica Bodogai
Journal:  Methods Mol Biol       Date:  2014

10.  Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.

Authors:  Monica Bodogai; Catalina Lee Chang; Katarzyna Wejksza; Jinping Lai; Maria Merino; Robert P Wersto; Ronald E Gress; Andrew C Chan; Charles Hesdorffer; Arya Biragyn
Journal:  Cancer Res       Date:  2013-01-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.